MTSR

Metsera, Inc. (MTSR) | Rumor.io

Metsera

MTSR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)91%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MTSR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0.01% +0.01

Feb 5

MTSR shares have declined following Pfizer's acquisition of a weight-loss biotech company, which was previously partnered with Metsera.
The deal may impact Metsera's future prospects and earnings, particularly in the context of its data and 2025 earnings expectations.
Pfizer's acquisition may also have implications for REGENXBIO, another company in the same industry.

Generated by AI

Sentiment

Of the messages about MTSR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +57.14	66.81% -28.17
Bearish	—	—	0% -57.14	33.19% +28.17

Bullish· Nov 19

MTSR's acquisition for $2.2 billion is a strong valuation indicator for other companies in the industry.
Dehydratech, the technology acquired by MTSR, has broad applications and potential for significant growth.
MTSR's investment in CRWV is a bullish sign for the company's future prospects and potential for increased value.

Bearish· Feb 4

MTSR's core business is struggling to compete in the obesity market, with missed earnings and weakness in structure.
MTSR's oral wegovy sales growth will decline when a promotional offer ends in a few months, as scripts are only available at a discounted price.
MTSR's lack of R&D investment and patent issues with its obesity-related drugs make it vulnerable to competition from other companies, such as Eli.

Generated by AI

Topics

Of the messages about MTSR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	22.7%
Announcements	—	—	—	64.73%
Controversies	—	—	—	9.52%
Earnings	—	—	—	1.18%
Macro	—	—	—	1.58%
Technical Analysis	—	—	—	0.29%

Earnings· Nov 5

Novo Nordisk's Q3 sales beat expectations, but the company lowered its 2025 outlook due to headwinds from U.S. Medicare price controls and production uncertainty.
The company's new CEO faces a tough start, with the resignation of its head of manufacturing and upcoming job cuts, amidst soaring demand for its obesity and diabetes drugs.
Executives expressed confidence in closing the Metsera acquisition and maintaining leadership in the global obesity-drug market against Pfizer and Eli Lilly.

Announcements· Nov 21

Metsera, Inc. (MTSR) distributor term sheets are open, potentially enabling multi-country scaling and a milestone post-MEDICA.
NextNRG Inc (NXXT) has a 627,000 kWh production arc, providing real infrastructure math behind its story, and is comparable to MTSR.
NXXT's 299-bed site contract validates its ability to handle large-scale healthcare deployments, similar to MTSR's capabilities.

Controversies· Nov 5

The FTC has raised concerns about the merger filing between Novo Nordisk and Metsera, citing potential antitrust and competition concerns in the biotech sector.
The proposed acquisition of Metsera by Novo Nordisk may breach premerger review laws under the Hart-Scott-Rodino Act, according to the FTC.
Pfizer has responded to the Delaware Chancery Court ruling, stating it remains confident in the merits of its claims and believes Metsera has acted in breach of its contractual obligations.

Generated by AI

Community

Of the messages about MTSR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	57.58%	5.73%
Newcomers	0%	0%	42.42%	94.27%

Regulars· Nov 8

Metsera's IPO story started before the company's financials were complete, potentially affecting the bidding process and future stock performance.
Pfizer's merger agreement with Metsera has been amended, with the company's board reaffirming its support for the deal, but no details on the new terms have been disclosed.
The $86.25 per share acquisition price for Metsera represents a significant premium, sparking debate among regulars about the deal's merits and potential implications for Big Pharma's involvement in the obesity market.

Newcomers· Feb 4

New investors are cautioning against Metsera, Inc. (MTSR) due to its struggles in the obesity market and concerns about its earnings.
The company's lack of R&D and its dependence on obesity drugs, which may be losing patents or facing competition, are major concerns.
The FTC's notification to Novo (NVO) about the deal structure being potentially illegal is seen as a red flag, but its implications are still unclear.

Generated by AI

News

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of cash, shares in Oxford Nanopore and a contingent payout linked to the biotech firm Metsera. The pension fund manager, IP Group's largest shareholder with an 18.4% stake, has made two improved...

2mo agoYahoo Finance UK

Also Discussed

Investors talking about MTSR also mention

#	Name	Attention
1	Novo Nordisk A/S Sponsored ADRNVO	0.14%-0.04
2	ETNB - 89bio, Inc.	——
3	Eli Lilly and CompanyLLY	0.16%+0.07
4	Viking Therapeutics, Inc.VKTX	0.18%0
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
7	Revolution Medicines, Inc.RVMD	0.01%-0.01
8	TERN - Terns Pharmaceuticals, Inc.	——
9	Janux Therapeutics, Inc.JANX	0%0
10	Wave Life Sciences Ltd.WVE	0%+0

Metsera, Inc.

Location

Social

What share of all stock conversation is about MTSR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0.01% +0.01

Feb 5

MTSR shares have declined following Pfizer's acquisition of a weight-loss biotech company, which was previously partnered with Metsera.
The deal may impact Metsera's future prospects and earnings, particularly in the context of its data and 2025 earnings expectations.
Pfizer's acquisition may also have implications for REGENXBIO, another company in the same industry.

Generated by AI

Sentiment

Of the messages about MTSR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +57.14	66.81% -28.17
Bearish	—	—	0% -57.14	33.19% +28.17

Bullish· Nov 19

MTSR's acquisition for $2.2 billion is a strong valuation indicator for other companies in the industry.
Dehydratech, the technology acquired by MTSR, has broad applications and potential for significant growth.
MTSR's investment in CRWV is a bullish sign for the company's future prospects and potential for increased value.

Bearish· Feb 4

MTSR's core business is struggling to compete in the obesity market, with missed earnings and weakness in structure.
MTSR's oral wegovy sales growth will decline when a promotional offer ends in a few months, as scripts are only available at a discounted price.
MTSR's lack of R&D investment and patent issues with its obesity-related drugs make it vulnerable to competition from other companies, such as Eli.

Generated by AI

Topics

Of the messages about MTSR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	22.7%
Announcements	—	—	—	64.73%
Controversies	—	—	—	9.52%
Earnings	—	—	—	1.18%
Macro	—	—	—	1.58%
Technical Analysis	—	—	—	0.29%

Earnings· Nov 5

Novo Nordisk's Q3 sales beat expectations, but the company lowered its 2025 outlook due to headwinds from U.S. Medicare price controls and production uncertainty.
The company's new CEO faces a tough start, with the resignation of its head of manufacturing and upcoming job cuts, amidst soaring demand for its obesity and diabetes drugs.
Executives expressed confidence in closing the Metsera acquisition and maintaining leadership in the global obesity-drug market against Pfizer and Eli Lilly.

Announcements· Nov 21

Metsera, Inc. (MTSR) distributor term sheets are open, potentially enabling multi-country scaling and a milestone post-MEDICA.
NextNRG Inc (NXXT) has a 627,000 kWh production arc, providing real infrastructure math behind its story, and is comparable to MTSR.
NXXT's 299-bed site contract validates its ability to handle large-scale healthcare deployments, similar to MTSR's capabilities.

Controversies· Nov 5

The FTC has raised concerns about the merger filing between Novo Nordisk and Metsera, citing potential antitrust and competition concerns in the biotech sector.
The proposed acquisition of Metsera by Novo Nordisk may breach premerger review laws under the Hart-Scott-Rodino Act, according to the FTC.
Pfizer has responded to the Delaware Chancery Court ruling, stating it remains confident in the merits of its claims and believes Metsera has acted in breach of its contractual obligations.

Generated by AI

Community

Of the messages about MTSR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	57.58%	5.73%
Newcomers	0%	0%	42.42%	94.27%

Regulars· Nov 8

Metsera's IPO story started before the company's financials were complete, potentially affecting the bidding process and future stock performance.
Pfizer's merger agreement with Metsera has been amended, with the company's board reaffirming its support for the deal, but no details on the new terms have been disclosed.
The $86.25 per share acquisition price for Metsera represents a significant premium, sparking debate among regulars about the deal's merits and potential implications for Big Pharma's involvement in the obesity market.

Newcomers· Feb 4

New investors are cautioning against Metsera, Inc. (MTSR) due to its struggles in the obesity market and concerns about its earnings.
The company's lack of R&D and its dependence on obesity drugs, which may be losing patents or facing competition, are major concerns.
The FTC's notification to Novo (NVO) about the deal structure being potentially illegal is seen as a red flag, but its implications are still unclear.

Generated by AI

Metsera

Social

Feb 5

Bullish· Nov 19

Bearish· Feb 4

Earnings· Nov 5

Announcements· Nov 21

Controversies· Nov 5

Regulars· Nov 8

Newcomers· Feb 4

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

Also Discussed

Metsera, Inc.

Company Information

Location

Social

Feb 5

Bullish· Nov 19

Bearish· Feb 4

Earnings· Nov 5

Announcements· Nov 21

Controversies· Nov 5

Regulars· Nov 8

Newcomers· Feb 4

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

Also Discussed